Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Tax Provisions (2020 - 2025)

Cytek Biosciences' Tax Provisions history spans 6 years, with the latest figure at $40.0 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 5461.81% year-over-year to $40.0 million; the TTM value through Dec 2025 reached $36.6 million, up 9442.97%, while the annual FY2025 figure was $36.7 million, 11368.12% up from the prior year.
  • Tax Provisions reached $40.0 million in Q4 2025 per CTKB's latest filing, up from -$2.3 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $40.0 million in Q4 2025 to a low of -$2.8 million in Q1 2024.
  • Average Tax Provisions over 5 years is $1.8 million, with a median of $75000.0 recorded in 2021.
  • Peak YoY movement for Tax Provisions: tumbled 2390.0% in 2022, then surged 5461.81% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $1.6 million in 2021, then plummeted by 75.39% to $396000.0 in 2022, then crashed by 451.52% to -$1.4 million in 2023, then surged by 151.72% to $720000.0 in 2024, then soared by 5461.81% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Tax Provisions are $40.0 million (Q4 2025), -$2.3 million (Q3 2025), and -$1.2 million (Q2 2025).